Huons Lab revealed on Thursday that it has validated the potential of its Hi-Diffuse platform for next-generation biopharmaceuticals.
At the annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) in Colorado on Wednesday, Huons Lab presented groundbreaking research. The study demonstrated the feasibility of transforming antibodies and antibody-drug conjugates (ADCs) into subcutaneous injection (SC) formulations using recombinant human-derived hyaluronidase.
Prior to this, Huons Lab conducted extensive pharmacokinetic studies, comparing the application of Hi-Diffuse across 11 types of monoclonal antibodies (mAbs) and 3 types of ADCs.
The results conclusively showed that Hi-Diffuse application significantly enhanced drug bioavailability.
In animal trials, researchers administered high-concentration formulations of both ADC and Hi-Diffuse to mice. Comparative pharmacokinetic analysis revealed that the Hi-Diffuse-based high-concentration formulation boosted drug exposure by 116% to 162% and increased maximum serum drug concentration by 113% to 170% compared to conventional ADCs.
These findings suggest that Huons Lab’s Hi-Diffuse-based formulation technology could enable reduced dosing of antibody drugs for subcutaneous (SC) administration while maintaining comparable drug exposure and efficacy.
Moreover, the Hi-Diffuse platform has demonstrated potential as a versatile platform applicable to a wide range of next-generation biopharmaceuticals.
A spokesperson for Huons Lab stated that it believes its Hi-Diffuse platform-based formulation technology has applications beyond antibody and ADC-based therapies. It shows promise for developing subcutaneous formulations across various next-generation biopharmaceutical modalities. They’re committed to ongoing research and development to further expand the reach of this innovative technology.
